Date published: 2025-10-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

CrkRS Inhibitors

CrkRS inhibitors belong to a distinct chemical class of compounds that are designed to target and modulate the activity of the enzyme CrkRS, also known as cysteinyl-tRNA synthetase. This enzyme plays a crucial role in the protein synthesis machinery of cells by catalyzing the attachment of cysteine to its cognate transfer RNA (tRNA), which is an essential step in the process of protein translation. CrkRS inhibitors are small molecules or compounds specifically engineered to interfere with the normal function of CrkRS, thereby disrupting the correct incorporation of cysteine into nascent polypeptide chains during translation. The mechanism of action of CrkRS inhibitors typically involves binding to the active site of the CrkRS enzyme, thereby blocking it from effectively binding to cysteine and transferring it to tRNA molecules. This interference leads to the misincorporation of non-cognate amino acids into the growing polypeptide chain, resulting in the production of dysfunctional proteins. These dysfunctional proteins can disrupt normal cellular processes, and their accumulation may ultimately lead to cell death. The development and study of CrkRS inhibitors are primarily driven by their utility in basic research and drug discovery, as they can serve as valuable tools for investigating the consequences of protein mistranslation and exploring its implications for various cellular pathways. Additionally, these inhibitors may offer insights into the fundamental biology of protein synthesis and its regulation, which could have broader implications for understanding cellular function and disease mechanisms.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$36.00
$149.00
11
(1)

This compound is known to disrupt RNA processing and could potentially impact CrkRS mRNA stability, leading to decreased protein expression.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

As an intercalating agent, doxorubicin can inhibit RNA synthesis, which may indirectly reduce CrkRS expression.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

It inhibits eukaryotic protein synthesis, potentially reducing the overall levels of many proteins, including CrkRS.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

This compound binds to DNA and inhibits RNA synthesis, which could lead to reduced transcription of the CrkRS gene.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin inhibits mTOR, a kinase that can regulate protein synthesis, possibly affecting CrkRS expression levels.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

As a kinase inhibitor, sorafenib might downregulate signal transduction pathways involved in CrkRS expression.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

This is a multi-targeted receptor tyrosine kinase inhibitor that could affect signaling pathways regulating CrkRS expression.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

By inhibiting certain tyrosine kinases, imatinib may impact signaling cascades that control CrkRS gene transcription.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Gefitinib targets EGFR, potentially altering downstream signaling pathways that might influence CrkRS expression.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

Similar to gefitinib, erlotinib inhibits EGFR and may affect signaling pathways related to CrkRS expression.